A-PVP
α-pyrrolidinopentiophenone
Viewing r1 — Apr 26, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
α-PVP (α-pyrrolidinopentiophenone) — also known as Flakka — is a synthetic stimulant of the cathinone class. It is a close structural relative of MDPV, with even greater dopamine selectivity.[1][2] It blocks dopamine and norepinephrine recycling in the brain,[3] flooding reward circuits with dopamine and driving intense stimulation.
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
cocaine, amphetamine, methamphetamine +2 morecocaine, amphetamine, methamphetamine, MDPV, methylphenidate show less
α-PVP emerged around 2011 as a direct replacement for MDPV and other bath salt cathinones that had just been banned.[2] It gained international attention during the 2014–2015 Flakka epidemic in Florida, when erratic, violent, and delusional public behavior drew intense media coverage. Despite permanent scheduling in the US in 2017 and EU-wide control in 2016, α-PVP remains prevalent in forensic casework across Europe.[4]
Subjective effects include euphoria, sharp focus, increased energy, and a compulsive compulsive redosing urge. The experience is narrowly dopaminergic — driven reward and motivation without the warmth of serotonin-active drugs like mephedrone.[5] Paranoia, hallucinations, aggression, and cardiovascular strain are characteristic unsought effects, especially after repeated use.
α-PVP produces rapid psychological dependence and carries high risk of cardiovascular emergency, psychosis, and muscle breakdown.[6] Compulsive redosing is the central danger — extreme dopamine selectivity creates a relentless drive to use again, and each additional dose raises the risk of acute psychosis, heart crisis, and kidney injury.[2][4] The evidence base is largely preclinical; the first controlled human pharmacokinetic data were not published until 2025.[7]
History[edit]
Discovery
α-PVP is a structural analog of pyrovalerone, a clinical anti-fatigue compound developed in the 1960s.[5][8] The exact date and laboratory of first synthesis have not been confirmed, though the compound likely dates to early pyrovalerone analog patent work from that era.[8]
Emergence and the "Flakka" epidemic
α-PVP was identified by European drug monitoring authorities in 2011[9] and appeared in US clinical specimens the same year.[10] It spread as a direct replacement for MDPV and other newly banned bath salt cathinones.[2][11] It gained international notoriety in 2014–2015 when erratic, violent, and delusional incidents in Broward County, Florida drew intense media coverage.[5][8]
Scheduling and modern prevalence
The US DEA placed α-PVP under Schedule I in 2014, with permanent placement in 2017.[12] EU-wide controls followed by Council Decision in 2016.[9] α-PVP remains prevalent in European forensic casework, and its scaffold continues to generate next-generation designer cathinones.[13][4][14]
The street name "Flakka" — sometimes also "Gravel" — became synonymous with α-PVP during the 2014–2015 media cycle covering bizarre behavioral incidents in South Florida. Concurrently, reports of traffic accidents caused by α-PVP-impaired drivers in Japan prompted domestic regulatory action.[15]
Chemistry[edit]
Structural class
α-PVP belongs to the pyrrolidinophenone subclass of synthetic cathinones — the same structural family as MDPV and pyrovalerone.[8][5] Its molecular formula is C₁₅H₂₁NO (molecular weight 231.33 g/mol).
It differs from MDPV by the absence of a methylenedioxy group on the phenyl ring, and from pyrovalerone by the absence of one methyl group.[3]
Pharmacology[edit]
Mechanism of action
α-PVP blocks the proteins that normally recycle dopamine and norepinephrine out of the brain's signaling gaps.[1] Unlike amphetamines, it does not force their release — it amplifies signals already being sent.[3][16] Its selectivity for dopamine over serotonin far exceeds cocaine's, producing intense reward-and-drive stimulation without serotonin's warmth.[1][2]
Pharmacokinetics
Human pharmacokinetic data come from a single observational study of intranasal use.[7] After snorting 10 or 20 mg, peak drug levels in oral fluid were reached at 47–60 minutes — notably later than related cathinones, possibly reflecting the pyrrolidine ring's effect on absorption.[7]
Metabolism
The body primarily breaks α-PVP down by opening its pyrrolidine ring, producing degradation products detectable in urine.[7][10] Bioavailability, protein binding, and half-life have not been characterized by any route.
Neuroscience[edit]
Where it acts
α-PVP floods the brain's main reward region — the nucleus accumbens — with dopamine immediately after use.[15][16] This surge drives the intense craving and compulsive urge to use again that define the α-PVP experience.
Why it matters
α-PVP activates the brain's wanting system more than its pleasure system — the dopamine surge creates craving and motivation rather than sustained satisfaction. The result is relentless redosing despite diminishing euphoria.
Chronic high-dose use damages the brain directly. Memory and spatial learning are impaired through energy failure inside brain cells,[17] and repeated use produces brain inflammation with sex-dependent patterns — males develop widespread brain inflammation, while females show predominantly peripheral inflammatory changes.[18]
The dose threshold for cognitive damage in humans is unknown — animal data show a clear effect, but translation to human use patterns has not been studied.[17] In animals, females show greater locomotor sensitivity[19][20][21] and different inflammatory patterns[18] compared to males, but whether this translates to differential human risk is unknown. Whether brain changes reverse with cessation has not been studied.
Subjective Effects[edit]
The α-PVP experience is narrow and driven — a surge of motivation, focus, and reward without the social warmth or perceptual richness of other stimulants. Compulsive redosing is not incidental but pharmacological: the dopamine surge creates relentless wanting, and each dose renews the urge to use again.
Compared to cocaine, α-PVP produces qualitatively similar but more potent dopaminergic stimulation — rhesus monkeys cannot distinguish the two in behavioral tests.[22] Against its closest relative MDPV, α-PVP achieves even greater dopamine selectivity[2] and a comparable compulsive-use profile.
Effect Grid
At common doses, the full stimulant experience manifests: pronounced euphoria, strong psychomotor activation, thought acceleration, and marked sociability. Confidence and motivation increase substantially. Time distortion (compression) is typical, with hours passing subjectively faster.
Cardiovascular effects become significant — tachycardia, elevated blood pressure, and peripheral vasoconstriction. Appetite suppression is complete. Bruxism and jaw clenching are common. Diaphoresis (sweating) may occur. Body temperature begins to rise.
Compulsive redosing becomes a prominent feature at this tier, particularly via smoked and insufflated routes. Sleep is impossible for 3-6 hours. Functional impairment increases with repeated dosing within a session.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Touch enhancement · Peripheral misidentification · Auditory distortion · Music enhancement · Auditory misinterpretation · Spatial disorientation · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Visual haze / noise · Brightness alteration · Visual drifting · Visual acuity suppression · Color enhancement · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Tinnitus · Vestibular distortion · Touch suppression · Auditory hallucinations · External hallucinations · Persisting hallucinations · Shadow people
Auditory misinterpretation · Spatial disorientation · Visual acuity enhancement · Visual processing acceleration · Dreaming enhancement · Visual haze / noise · Brightness alteration · Visual drifting · Visual acuity suppression · Color enhancement · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Tinnitus · Vestibular distortion · Touch suppression · Auditory hallucinations · External hallucinations · Persisting hallucinations · Shadow people
Pupil dilation · Restlessness · Insomnia · Physical fatigue · Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Dehydration sensation · Respiratory stimulation · Tactile euphoria · Temperature dysregulation · Trembling · Spontaneous body sensations · Headache · Bruxism · Sexual arousal enhancement · Involuntary body movements · Breathing alteration · Dizziness · Motor control impairment · Nausea · Tingling / electric sensations · Increased urination · Seizure threshold reduction · Bodily lightness · Nasal congestion · Vibrations / buzzing · Vomiting · Constipation · Tactile hallucination
Physical fatigue · Dry mouth · Excessive sweating · Body high · Heart rate perception changes · Muscle tension · Dehydration sensation · Respiratory stimulation · Tactile euphoria · Trembling · Spontaneous body sensations · Headache · Bruxism · Sexual arousal enhancement · Involuntary body movements · Breathing alteration · Dizziness · Motor control impairment · Nausea · Tingling / electric sensations · Increased urination · Seizure threshold reduction · Bodily lightness · Nasal congestion · Vibrations / buzzing · Vomiting · Constipation · Tactile hallucination
Cognitive dysphoria · Motivation enhancement · Motivation suppression · Immersion enhancement · Focus enhancement · Analysis enhancement · Analysis suppression · Cognitive impairment · Confusion · Information processing enhancement · Multiple thought streams · Novelty enhancement · Thought connectivity · Thought disorganization · Thought loops · Cognitive flexibility · Creativity suppression · Focus suppression · Information processing suppression · Memory fragmentation · Memory suppression · Pattern recognition enhancement · Creativity enhancement · Language enhancement · Memory enhancement · Thought organization · Thought deceleration · Delusions of sobriety · Language suppression · Delusions · Delirium
Immersion enhancement · Focus enhancement · Analysis enhancement · Analysis suppression · Cognitive impairment · Confusion · Information processing enhancement · Multiple thought streams · Novelty enhancement · Thought connectivity · Thought disorganization · Thought loops · Cognitive flexibility · Creativity suppression · Focus suppression · Information processing suppression · Memory fragmentation · Memory suppression · Pattern recognition enhancement · Creativity enhancement · Language enhancement · Memory enhancement · Thought organization · Thought deceleration · Language suppression · Delusions · Delirium
Anhedonia · Dysphoria · Emotional enhancement · Emotional lability · Empathy suppression · Mania
Emotional lability · Empathy suppression
Emotional susceptibility · Sociability suppression · Social disconnection · Communication enhancement · Sociability enhancement · Communication suppression · Flow state · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Sociability enhancement · Communication suppression · Flow state · Depersonalization · Derealization · Cognitive disconnection · Identity alteration
Timeline
Initial awareness of stimulation within 2-10 minutes of insufflation. Slight nasal burning followed by a building sense of alertness and mild mood shift.
Stimulation intensifies over 10-30 minutes. Euphoria, thought acceleration, and cardiovascular activation build progressively. Heart rate and blood pressure begin rising.
Maximum euphoria, psychomotor activation, and cardiovascular effects at 45-90 minutes. Tmax measured at 47-60 minutes in PK studies. Compulsive redosing urge is strongest during this phase.
Sustained stimulation with gradually declining euphoria over 1-2 hours. Residual cardiovascular activation persists. Anxiety and restlessness may replace euphoria, particularly at higher doses.
Stimulation fades over 1-2 hours. Fatigue, irritability, and dysphoria emerge as dopaminergic effects wane. Appetite begins returning.
Residual fatigue, low mood, and mild cognitive impairment lasting 2-6 hours. Sleep quality may be disrupted even after subjective effects resolve.
⚠ Do not drive or operate machinery until after a full sleep cycle following use.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 10 days
- Physical
- Low
- Psychological
- High
- Compulsive redosing
- High
- Dose escalation
- High
- Cross-tol.
- cocaine · amphetamine · methamphetamine
Toxicity
Acute toxicity
No lethal dose has been established. The acute toxicity pattern is a cascade of overstimulation: rapid heart rate, high blood pressure, elevated body temperature, seizures, extreme agitation, muscle breakdown, and kidney injury.[23][24]
In 34 Finnish fatal cases from 2018–2023, blood concentrations ranged from 0.03 to 2.6 mg/L.[4] The wide range reflects polydrug involvement rather than an intrinsic lethal threshold — only 1.7% of fatal synthetic cathinone cases involved α-PVP alone, and α-PVP was implicated in the cause of death in 29% of cases where it was detected.[4]
α-PVP is not detected by standard urine drug screens. Confirmation requires specialized laboratory testing.[8][7] Emergency physicians should consider synthetic cathinone exposure in patients presenting with unexplained stimulant toxicity and negative routine screening.
Muscle breakdown
α-PVP damages muscle through two routes. Indirect damage results from overstimulation — elevated body temperature and sustained muscle hyperactivity. Direct damage occurs at the cellular level: α-PVP impairs energy production inside muscle cells, increasing oxidative stress.[6] Muscle breakdown-induced kidney injury is a prominent feature of severe toxicity.[25]
Cognitive toxicity
Repeated high-dose use impaired spatial learning and memory in rats through brain energy failure.[17] Lower doses did not produce these effects. The dose threshold for cognitive damage in humans has not been characterized.
Polydrug fatality context
In 118 Finnish post-mortem cases from 2018–2023, α-PVP was present alongside opioids, stimulants, or sedatives in 69–92% of cases.[4] Mixed synthetic cathinone poisoning dramatically elevates toxicity risk compared to single-substance exposure.[26]
Psychological risks
α-PVP's extreme dopamine selectivity is strongly associated with acute psychosis. Paranoia, hallucinations, aggression, and severe anxiety are documented in clinical case series.[27][8] High dopamine selectivity carries the highest psychosis risk among synthetic cathinones.[27]
Behavioral toxicity extends to loss of control: erratic public behavior, aggression, and impaired driving were documented during the Flakka epidemic and in Japanese traffic accident reports.[8][15] Chronic use produces brain inflammation with sex-dependent patterns.[18]
Tolerance & dependence
α-PVP has among the highest reinforcing potency of any cathinone tested — 100% of rats in self-administration studies acquired the behavior.[2] Its reinforcing effectiveness exceeds that of cocaine.[11]
Tolerance develops through dopaminergic neuroadaptation. Lasting molecular changes after withdrawal are documented in the closely related MDPV.[28] Physical withdrawal has not been characterized in human studies; psychological dependence potential is strongly supported by preclinical data. inferred
Drug Interactions
The interaction profile is poorly characterized, with no substance-specific combination studies in humans.
Stimulants and norepinephrine-active drugs: Combined use adds cardiovascular stress — higher blood pressure, faster heart rate, and elevated body temperature from additive stimulation. inferred
Tramadol: Listed as potentially lethal in community databases. The proposed mechanism involves tramadol's combined serotonin/norepinephrine activity and weak opioid effects raising the risk of seizures and cardiovascular toxicity. No published case reports have been identified. safety citation needed
Opioids: The dominant fatality context. In Finnish post-mortem data, 69–92% of α-PVP-positive cases involved concurrent opioids, stimulants, or sedatives.[4] Mixed synthetic cathinone poisoning dramatically elevates toxicity.[26]
Alcohol: alcohol pre-exposure modifies α-PVP's reward and aversion balance in animal studies.[29] The direction and magnitude in humans remain uncharacterized.
Other synthetic cathinones: Combining α-PVP with MDPV produced significantly greater stimulant effects than either drug alone, particularly in females.[19]
Contraindications
Cardiovascular disease: Heart conditions including arrhythmias, high blood pressure, coronary artery disease, and structural heart disease are absolute contraindications. α-PVP produces dose-dependent increases in heart rate and blood pressure,[30] and cardiovascular collapse is a component of fatal toxicity.[24]
Psychotic disorders and bipolar disorder: History of psychosis or bipolar disorder is an absolute contraindication given documented association with acute psychotic episodes and paranoid ideation.[27][8]
Seizure disorders: Seizures are a documented component of α-PVP toxicity,[24] representing a contraindication for those with epilepsy or lowered seizure threshold.
Kidney impairment: Muscle breakdown-induced kidney injury is a prominent feature of severe toxicity.[6][25] Pre-existing kidney disease increases vulnerability.
Pregnancy: No reproductive toxicity data exist for α-PVP. As a potent sympathomimetic, it poses theoretical risks to fetal development and placental blood flow. inferred
Harm Reduction[edit]
Forms & Identification
α-PVP is most commonly encountered as a white or off-white crystalline powder. Standard urine drug screens do not detect it — confirmation requires specialized laboratory testing. Visual appearance alone cannot confirm identity; substitution with other pyrrolidinophenones or cathinones is a known risk in unregulated supply.
Purity variation has direct implications for dosing. Start with the lowest possible amount and allow adequate time before considering redosing, particularly with oral administration where onset is slower and premature redosing is common.
Guidelines
- Test substance identity with reagent kits before use
- Pre-measure a single session's amount and store the remainder out of reach
- Avoid smoked or injected routes, which produce the most intense rush and strongest compulsive redosing urge
- Begin with threshold doses when encountering new material, regardless of prior experience
- Maintain hydration but avoid over-hydration — drink to thirst
- Eat a meal before use; stimulant appetite suppression makes eating difficult afterward
- Do not use alone — have a trusted person present who can recognize escalating paranoia or agitation
- Set a firm time limit; α-PVP sessions that extend beyond initial plans are the norm, not the exception
- Avoid sequential-day use; allow at minimum several days between sessions to reduce tolerance and neuroadaptive risk
Set & Setting
α-PVP's extreme dopamine selectivity makes set and setting less protective than with most psychoactives. At lower doses, a calm, familiar environment with trusted companions can reduce anxiety and paranoia. At higher doses or after repeated administrations, pharmacological compulsion overrides context — paranoia and psychosis can emerge regardless of surroundings.
Planning to use "just once" reliably fails with α-PVP. Pre-determining a total amount and removing access to remaining supply before a session begins is more effective than in-the-moment restraint.
Aftercare & integration. The comedown brings exhaustion, depressed mood, irritability, and intense cravings. Sleep recovery is the first priority — a dark, quiet room and patience are the primary tools.
Eat as soon as possible after stimulant effects subside. Calorie-dense, easy-to-digest food helps restore depleted energy. Hydrate steadily but not excessively. Expect mood and motivation to remain low for 24–72 hours — this is neurochemical rebound effect, not a permanent state.
If paranoia, hallucinations, or thought disorganization persist beyond 24 hours after last use, seek medical evaluation. Stimulant-induced psychosis typically resolves with cessation and sleep, but prolonged episodes require professional assessment.
Recovery & Support
α-PVP's extreme reinforcing potency means the transition from use to compulsive use happens faster than with most stimulants. Recognizing the pattern — sessions extending beyond planned limits, escalating doses, inability to discard remaining supply, using alone — is the critical first step.
No α-PVP-specific treatment protocols exist. Approaches developed for cocaine and methamphetamine dependence are generally applied, including cognitive behavioral therapy and contingency management. Medical evaluation is advisable for anyone with a history of regular use given documented risks of muscle damage, kidney injury, and brain inflammation.
Support resources include SAMHSA's National Helpline (1-800-662-4357), local addiction services, and peer support communities.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: The line between uncomfortable stimulation and medical emergency includes: chest pain or pressure, seizures, loss of consciousness, body temperature so high it can be felt through clothing, extreme confusion or delirium, aggressive behavior unresponsive to verbal calming, or inability to stop repetitive movements.
Immediate steps:
- 1. Call emergency services immediately if any of the above signs are present
- 2. Move the person to a cool, quiet environment
- 3. Remove objects that could cause injury during agitation
- 4. Do not physically restrain unless there is immediate danger to self or others — restraint can worsen elevated body temperature and muscle breakdown
- 5. If the person is unconscious and breathing, place them in the recovery position
- 6. Monitor breathing and temperature while waiting for help
What to tell the dispatcher: Name the substance (α-PVP, synthetic cathinone, or "Flakka"), approximate amount used, time of last dose, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
α-PVP is a controlled substance in most major jurisdictions, scheduled following the global synthetic cathinone regulation wave that began in 2011.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Temporary Schedule I from February 2014; permanent placement effective March 1, 2017. Also covered under the Federal Analogue Act as a cathinone structural analog.[12] |
| European Union | Controlled (EU Council Decision) | EMCDDA risk assessment completed November 2015; Council Decision requiring all member states to implement control measures enacted June 27, 2016.[9] |
| United Kingdom | Psychoactive substance (PSA 2016) | Covered under Psychoactive Substances Act 2016, effective May 26, 2016. Sale, distribution, and supply for human use prohibited.[31] |
| Australia | Schedule 9 (Prohibited Substance) | TGA scheduling decision effective April 2018. Sale, manufacture, distribution, and use prohibited without research permit.[32] |
| Canada | Likely Schedule III (CDSA) | Cathinone is listed as Schedule III under the Controlled Drugs and Substances Act. α-PVP-specific listing was not confirmed.[33] citation needed |
| Japan | Designated substance | Regulated following reports of traffic accidents involving α-PVP-impaired drivers by 2014–2015.[15] |
Legal status changes frequently and varies by jurisdiction. This information reflects known status as of the article's last review and is not legal advice.
references
- [1] ^abcPersson M, Vikingsson S, Kronstrand R, Green H (2024) Characterization of neurotransmitter inhibition for seven cathinones by a proprietary fluorescent dye method. — Drug Testing and Analysis doi:10.1002/dta.3547
- [2]
- [3] ^abcNguyen VT, Harris AC, Eltit JM (2024) Structural and functional perspectives on interactions between synthetic cathinones and monoamine transporters. — Advances in Pharmacology doi:10.1016/bs.apha.2023.09.001
- [4]
- [5] ^abcdKolanos R, Sakloth F, Jain AD, Partilla JS, Baumann MH, Glennon RA (2015) Structural Modification of the Designer Stimulant α-Pyrrolidinovalerophenone (α-PVP) Influences Potency at Dopamine Transporters. — ACS Chemical Neuroscience doi:10.1021/acschemneuro.5b00160
- [6] ^abcZhou X, Luethi D, Sanvee GM, Bouitbir J, Liechti ME, Krähenbuhl S (2019) Molecular Toxicological Mechanisms of Synthetic Cathinones on C2C12 Myoblasts. — International Journal of Molecular Sciences doi:10.3390/ijms20071561